Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.
- DOI
- 10.1007/s10637-015-0272-0
- Published
- 2015 Oct
- Container
- Investigational new drugs
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10637-015-0272-0,
title = {Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.},
author = {Gustavsson B and Carlsson G and Swartling T and Kurlberg G and Derwinger K and Björkqvist H and Odin E and Gibson F},
year = {2015},
journal = {Investigational new drugs},
doi = {10.1007/s10637-015-0272-0},
url = {https://doi.org/10.1007/s10637-015-0272-0}
}RIS
TY - JOUR TI - Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. AU - Gustavsson B AU - Carlsson G AU - Swartling T AU - Kurlberg G AU - Derwinger K AU - Björkqvist H AU - Odin E AU - Gibson F PY - 2015 JO - Investigational new drugs DO - 10.1007/s10637-015-0272-0 UR - https://doi.org/10.1007/s10637-015-0272-0 ER -
APA
B, G., G, C., T, S., G, K., K, D., H, B., E, O., & F, G. (2015). Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer.. Investigational new drugs. https://doi.org/10.1007/s10637-015-0272-0
Source records
- pubmed · retrieved 2026-09-26T16:44:26.706Z